FDA meeting rescheduled
This article was originally published in The Tan Sheet
Manufacturing Subcommittee of the Advisory Committee on Pharmaceutical Science, which was slated to meet March 21, will instead combine that agenda with next scheduled meeting May 21-22. Inaugural meeting of the subcommittee was cancelled due to war in Iraq; FDA was expected to outline its progress on the "Pharmaceutical cGMPs for the 21st Century: A Risk-Based Approach" initiative (1"The Tan Sheet" Sept. 2, 2002, p. 13)...
You may also be interested in...
FDA's risk-based inspection model will consider a product's breadth of use when assigning inspection priorities
The number of new drugs containing new active substances approved in the EU rose significantly in 2020, underpinned by a strong showing for orphan-designated products and a string of novel medicines for cancer and infectious diseases. Notable among the new clutch of approvals was the first ever COVID-19 vaccine, Pfizer/BioNTech's Comirnaty.
The Canadian medtech regulator has recommended updating its list of recognized medical device standards that manufacturers can rely on to demonstrate compliance with local safety, effectiveness and labeling requirements.